Chardan initiates Praxis with a Buy rating, highlighting its epilepsy pipeline, strong cash position, and billion-dollar potential of vormatrigine.
Latest Ratings for PRAX
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 2021 | HC Wainwright & Co. | Initiates Coverage On | Buy | |
| Aug 2021 | B of A Securities | Initiates Coverage On | Buy | |
| Apr 2021 | William Blair | Initiates Coverage On | Outperform |
